Maeve O’Reilly

2.9k total citations · 1 hit paper
45 papers, 1.5k citations indexed

About

Maeve O’Reilly is a scholar working on Oncology, Immunology and Pathology and Forensic Medicine. According to data from OpenAlex, Maeve O’Reilly has authored 45 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Oncology, 8 papers in Immunology and 7 papers in Pathology and Forensic Medicine. Recurrent topics in Maeve O’Reilly's work include CAR-T cell therapy research (29 papers), Lymphoma Diagnosis and Treatment (7 papers) and Biosimilars and Bioanalytical Methods (6 papers). Maeve O’Reilly is often cited by papers focused on CAR-T cell therapy research (29 papers), Lymphoma Diagnosis and Treatment (7 papers) and Biosimilars and Bioanalytical Methods (6 papers). Maeve O’Reilly collaborates with scholars based in United Kingdom, Ireland and United States. Maeve O’Reilly's co-authors include Ian B. Jeffery, Paul D. Cotter, David Kerins, R. Paul Ross, P. Lynn Hayes, Alice Lucey, Aileen Hogan, Michael G. Molloy, Margaret Humphreys and Eamonn M.M. Quigley and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Gut.

In The Last Decade

Maeve O’Reilly

39 papers receiving 1.5k citations

Hit Papers

Exercise and associated dietary extremes impact on gut mi... 2014 2026 2018 2022 2014 250 500 750 1000

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Maeve O’Reilly United Kingdom 10 866 635 349 136 133 45 1.5k
Allison Clark United States 17 795 0.9× 412 0.6× 102 0.3× 174 1.3× 119 0.9× 20 1.3k
Mònica Aguilera Spain 17 695 0.8× 327 0.5× 145 0.4× 93 0.7× 172 1.3× 29 1.4k
Mae J. Ciancio United States 17 948 1.1× 402 0.6× 79 0.2× 97 0.7× 178 1.3× 40 1.6k
Karolina Kaźmierczak-Siedlecka Poland 20 648 0.7× 269 0.4× 190 0.5× 48 0.4× 91 0.7× 54 1.1k
Raffaela Pero Italy 26 760 0.9× 116 0.2× 131 0.4× 90 0.7× 186 1.4× 49 1.5k
Aileen Hogan Canada 9 1.4k 1.6× 743 1.2× 88 0.3× 161 1.2× 287 2.2× 11 2.0k
Séverine Vincent France 20 400 0.5× 181 0.3× 93 0.3× 192 1.4× 158 1.2× 55 1.5k
Adriaan A. van Beek Netherlands 16 848 1.0× 402 0.6× 217 0.6× 25 0.2× 71 0.5× 25 1.5k
R. W. Summers United States 19 252 0.3× 491 0.8× 365 1.0× 273 2.0× 322 2.4× 36 2.1k
Junjie Mei United States 14 558 0.6× 280 0.4× 196 0.6× 106 0.8× 72 0.5× 23 1.6k

Countries citing papers authored by Maeve O’Reilly

Since Specialization
Citations

This map shows the geographic impact of Maeve O’Reilly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maeve O’Reilly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maeve O’Reilly more than expected).

Fields of papers citing papers by Maeve O’Reilly

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maeve O’Reilly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maeve O’Reilly. The network helps show where Maeve O’Reilly may publish in the future.

Co-authorship network of co-authors of Maeve O’Reilly

This figure shows the co-authorship network connecting the top 25 collaborators of Maeve O’Reilly. A scholar is included among the top collaborators of Maeve O’Reilly based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maeve O’Reilly. Maeve O’Reilly is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Vonberg, Frederick W., Imran Malik, Maeve O’Reilly, et al.. (2025). Neurotoxic complications of chimeric antigen receptor (CAR) T-cell therapy. Journal of Neurology Neurosurgery & Psychiatry. 96(7). 665–678. 1 indexed citations
3.
Rampotas, Alexandros, Sabine Pomplun, Teresa Marafioti, et al.. (2025). Clonal evolution and the risk of secondary myeloid neoplasia following chimeric antigen receptor T-cell therapy. Haematologica. 110(11). 2812–2818.
4.
Díaz, Juan Manuel Mancilla, Saurabh Dahiya, Maeve O’Reilly, et al.. (2024). Cohort Comparison of Therapy-Related Myeloid Neoplasms after CAR T-Cell Therapy, Autologous Stem Cell Transplant, and Standard Cancer Therapies. Blood. 144(Supplement 1). 7239–7239.
5.
O’Reilly, Maeve, Lorna Neill, Simon M. Collin, et al.. (2024). High pretreatment disease burden as a risk factor for infectious complications following CD19 chimeric antigen receptor T‐cell therapy for large B‐cell lymphoma. HemaSphere. 8(1). e29–e29. 5 indexed citations
6.
McCourt, Orla, et al.. (2024). Single‐centre experience of implementing physiotherapist‐led prehabilitation for chimeric antigen receptor T cell therapy. SHILAP Revista de lepidopterología. 5(5). 1033–1037. 1 indexed citations
7.
Chen, Daniel, Maeve O’Reilly, Ryan Low, et al.. (2024). CD19‐targeting chimeric antigen receptor T‐cell therapy is safe and effective for intra‐cardiac B cell non‐Hodgkin lymphoma. SHILAP Revista de lepidopterología. 5(6). 1283–1289. 1 indexed citations
8.
O’Reilly, Maeve, Michelle Cummins, Emma Nicholson, et al.. (2024). Practice guideline: Preparation for CAR T‐cell therapy in children and young adults with B‐acute lymphoblastic leukaemia. British Journal of Haematology. 204(5). 1687–1696. 1 indexed citations
9.
O’Reilly, Maeve, et al.. (2024). Malnutrition and cachexia are associated with poor CAR T-cell therapy outcomes including survival. Clinical Nutrition ESPEN. 62. 206–215. 5 indexed citations
10.
Marzolini, Maria A. V., Irfan Kayani, Ben Carpenter, et al.. (2024). The Effect of the Pre‐Transplant Disease Status on the Outcome for Recipients of T‐Cell Depleted Allogeneic Haematopoietic Stem Cell Transplants for Large B Cell Lymphomas. European Journal Of Haematology. 114(3). 545–555.
11.
Roddie, Claire, Lorna Neill, Wendy Osborne, et al.. (2023). Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma. Blood Advances. 7(12). 2872–2883. 64 indexed citations
12.
Mullanfiroze, Khushnuma, Arina Lazareva, Jan Chu, et al.. (2022). CD34+-selected stem cell boost can safely improve cytopenias following CAR T-cell therapy. Blood Advances. 6(16). 4715–4718. 30 indexed citations
14.
O’Reilly, Maeve, Stuart J. Ings, Katarzyna Aleksandra Jalowiec, et al.. (2022). A novel predictive algorithm to personalize autologous T-cell harvest for chimeric antigen receptor T-cell manufacture. Cytotherapy. 25(3). 323–329. 13 indexed citations
15.
Marzolini, Maria A. V., Lorna Neill, Maeve O’Reilly, Karl S. Peggs, & Claire Roddie. (2021). Lymphocyte morphology in a patient receiving CD19 chimeric antigen receptor T‐cell therapy for mantle cell lymphoma. SHILAP Revista de lepidopterología. 3(1). 245–246. 1 indexed citations
16.
Shafat, Manar, Harpreet Hyare, Lorna Neill, et al.. (2021). Pembrolizumab for the treatment of progressive multifocal leukoencephalopathy following anti‐CD19 CAR‐T therapy: a case report. SHILAP Revista de lepidopterología. 2(4). 848–853. 7 indexed citations
18.
Clarke, Siobhan F., Eileen F. Murphy, Órla O’Sullivan, et al.. (2014). Exercise and associated dietary extremes impact on gut microbial diversity. Gut. 63(12). 1913–1920. 1044 indexed citations breakdown →
19.
O’Reilly, Maeve. (1995). Radiological Case of the Month. Archives of Pediatrics and Adolescent Medicine. 149(9). 1029–1029. 2 indexed citations
20.
O’Reilly, Maeve, et al.. (1994). Hajdu-Cheney syndrome.. Annals of the Rheumatic Diseases. 53(4). 276–279. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026